Abstract
Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma. For each condition, using octreotide was associated with doubled survival time. Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.
| Original language | English |
|---|---|
| Pages (from-to) | 514-525 |
| Number of pages | 12 |
| Journal | International Journal of Technology Assessment in Health Care |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1998 |
Funding
Carcinoid tumor is an uncommon malignancy with an incidence of approximately 1.5 cases per 100,000 (18) and accounting for approximately 55% of gastrointestinal The project was supported by Novartis Pharmaceuticals Corporation (formerly Sandoz Pharmaceuticals Corporation.) Warren H. Schonfeld, Eric P. Elkin, Eugene A. Woltering, Irvin M. Modlin, Lowell Anthony, Kathleen F. Villa, and Martin Zagari own no stock or options in Novartis Pharmaceuticals Corporation. Dr. Woltering receives financial support from Novartis Pharmaceuticals Corporation for some of his research, as well as honoraria for work through their speaker's bureau. We thank Novartis Pharmaceuticals Corporation for funding this modeling effort and manuscript.
| Funders | Funder number |
|---|---|
| Sandoz Pharmaceuticals Corporation | |
| Novartis Pharmaceuticals Corporation |
ASJC Scopus subject areas
- Health Policy
